Introduction {#s1}
============

Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer death among women in the United States (6% of cancer deaths); in 2015, it is estimated that 14,180 women will die from the disease (Siegel et al., [@B42]). The standard treatment for patients with advanced disease is initial debulking surgery followed by carboplatin-paclitaxel combination chemotherapy (Marsh, [@B27]). Five-year overall survival remains around 45% (Marsh, [@B27]), yet there is a wide inter-patient variation in response. Currently there are few reliable prognostic biomarkers for the classification of patients and treatment response.

Platinating agents, such as carboplatin, interfere with DNA via inter-strand, intra-strand, and DNA-protein crosslinks, thereby causing DNA damage and prevention of cell division and growth, resulting in cell-cycle arrest and apoptosis (Dekou et al., [@B5]). Although platinum-based drugs are widely used in cancer treatment, many tumors are completely resistant to these drugs, and no clinical response is attained. Major molecular mechanisms underlying this resistance might involve alteration in platinum inactivation or reduced intracellular accumulation by uptake/efflux transporters, increased repair of adducts, increased adduct tolerance or failure of apoptotic pathway. Taxane agents, such as paclitaxel, are commonly used chemotherapeutic drugs often in combination with platinating agents. Taxanes block cell division by binding to α-tubulin, stabilizing the microtubules, thus resulting in cell death (Huizing et al., [@B18]; Jordan and Wilson, [@B20]). The development of taxane resistance is common, where response has been linked to metabolism and disposition molecules, such as, cytochrome P450s and drug transporters (e.g., *ABCB1, ABCG2, ABCC1, ABCC2*, and *SLC01B3*; Hewett et al., [@B15]; Rodriguez-Antona, [@B41]). In particular, studies in colorectal cell lines and tumor tissue have shown that CYP2C8 may play a role in paclitaxel resistance and the CYP3A may be involved in local inactivation of paclitaxel (Martinez et al., [@B28]; Garcia-Martin et al., [@B12]). Additionally, *CYP2C8* and *CYP3A4* are high involved in the metabolism of paclitaxel in patients with ovarian cancer (Bergmann et al., [@B1]), while breast cancer patients carrying the ^\*^3 variant of *CYP2C8* have better response to paclitaxel, but at an increase in peripheral neurotoxicity (Hertz et al., [@B14]).

However, these molecules do not explain all the variation in taxane response or resistance. Inherited variation in many of the genes encoding these molecules have been assessed for association with clinical outcome with inconsistent results (Peethambaram et al., [@B36]; Johnatty et al., [@B19]; White et al., [@B45]); genome-wide searches to date have also failed to identify variants associated with outcome after correction for genome-wide testing (*p* \< 5 × 10^−8^). Patient-derived cell line based model systems represent a novel way to identify genomic predictors of drug response. Although lymphoblastoid cell lines (LCLs) derived from participants in the international HapMap project have been used to identify genomic predictors of cytotoxic effects of various chemotherapeutic agents (Li et al., [@B23], [@B22]; Niu et al., [@B33]; Huang et al., [@B17]; Wu et al., [@B47]), they are limited as they are not derived from the EOC population but from healthy individuals.

In this study, we generated LCLs derived from Mayo Clinic EOC patients, conducted *in vitro* cytotoxic studies, and associated *in vitro* drug response phenotypes with germline genotype. Utilizing patient-derived LCLs, as opposed to commercially available LCLs, allows us to screen and directly correlate *in vitro* phenotypes and clinical responses. These genome-wide association scans (GWAS) should contribute to the identification of predictive markers of treatment responses and ultimately improve clinicians\' ability to tailor therapy decisions for EOC patients.

Materials and methods {#s2}
=====================

Patients, lymphoblastoid cell lines, and cytotoxicity assays
------------------------------------------------------------

Prior to initiation of chemotherapy, ovarian cancer patients diagnosed at the Mayo Clinic between 2000 and 2003 provided blood for immediate germline DNA extraction and for the creation of Epstein Barr Virus (EBV)-transformed LCLs. Samples from 74 patients were successfully transformed and subjected to *in vitro* drug testing. All patients provided informed written consent, including for passive and active follow-up, using protocols approved by the appropriate Institutional Review Board at the Mayo Clinic in Rochester, MN.

*In vitro* cellular chemo-sensitivity studies of LCLs were performed in two batches (*N* = 33, *N* = 41) using identical procedures and assays. Cells were maintained in RPMI1640 media supplemented with 2 mM L-glutamine, and 15% fetal bovine serum at 37°C under 5% CO~2~. Following 24 h incubation, LCLs were treated with increasing concentrations of carboplatin and/or paclitaxel (in duplicate). The concentrations of carboplatin were 0, 5, 10, 20, 40, 80, and 128 μM, while for paclitaxel were 0, 4.5, 7.5, 10, 20, 40, and 80 nM when used as single agents. In drug combination experiments, we used half of the doses for each drug in increasing doses (i.e., 2.5 μM carboplatin + 2.25 nM paclitaxel for "dose level 1" and so on). Cell viability 48 h post-treatment was determined using standard MTT assay (Li et al., [@B23]; Gamazon et al., [@B10]). Caspase3/7 (Promega) apoptosis assays were performed at the same time in parallel plates. A Synergy 3 plate reader (BioTek Instruments) was used to read absorbance (cell viability using MTT) or fluorescence (for caspase3/7 activity) intensities.

Four parameter logistic dose response curves $\left. Y_{i}~ = ~\alpha + (\beta - \alpha)\slash\left( {1 + \left\lbrack \frac{D_{i}}{\theta} \right\rbrack^{\phi}} \right) \right.$ were fit to the *in vitro* drug response measurements (cell survival and caspase3/7 activity assays) for each LCL and treatment (paclitaxel, carboplatin, and combination), where *Y*~*i*~ is the measurement at dose *i* (*Di*), α α is the estimated bottom of the curve (i.e., measurement as *Di* → ∞), β → ∞), β is the estimated top of the curve (i.e., measurement as *Di* → 0), ϕ is the slope of the curve, and θ is the inflection point of the curve (i.e., concentration giving a response half way between the top and bottom of the curve). The estimated inflection point of the curve was used as the drug response phenotype. That is, using these dose-response curves, we estimated the relative IC50 (effective dose that kills 50% of the cells) for MTT cell viability and the relative EC50 (concentration required to induce caspase 3/7 activity by 50%) for caspase3/7 activity. For simplicity of presentation, we will refer to these quantitative values as the IC50 for the MTT cytotoxicity assays and EC50 for the caspase 3/7 assays. We then applied rank-based inverse Gaussian transformation (i.e., Van de Waerden rank transformation). Summaries of the IC50 and EC50 values for both experimental batches are presented in Supplemental Table [1](#SM1){ref-type="supplementary-material"}. We observed a high degree of correlation between many of the drug response phenotypes, as expected (Supplemental Figure [1](#SM1){ref-type="supplementary-material"}).

Genotyping and statistical methods
----------------------------------

Germline DNA was genotyped on the Illumina Infinium 610K array, as previously described (Pharoah et al., [@B37]). All samples had genotype call rate \>95% and were predicted by STRUCTURE (Pritchard et al., [@B40]) analysis to have greater than 80% European ancestry. SNPs were excluded with call rate \< 95%, Hardy-Weinberg Equilibrium *p* \< 10^−4^, or no variation in this set. Using the 1000 Genomes Project (Durbin et al., [@B7]) as reference, imputation was completed with *mach* and *minimac* in a two-step process (Howie et al., [@B16]), resulting in data on more than 30 million SNPs. Assessment of imputation quality was completed and high quality imputed markers (r^2^≥ 0.30 and MAF ≥ 0.01) were retained (6,243,550 SNPs).

The association of each SNP with *in vitro* drug response phenotypes IC50 or EC50 was evaluated with linear models using the expected genotype or "dosage" (i.e., additive or dose-response/trend model). Thus, a negative effect estimate indicates that the carriers of the minor/rare allele have lower IC50 (EC50) values (i.e., were more "sensitive" to treatment). The two *in vitro* experimental batches were analyzed separately followed by meta-analysis was conducted using *metal* (Willer et al., [@B46]), with weights applied for the number of samples in each group. We completed the GWAS analyses for each individual *in vitro* drug response phenotype, as opposed to a combined analysis with all phenotypes model together, due to the difference in mechanism of action between the drugs (i.e., not in the same drug class; Fridley et al., [@B9]). For annotation of results across gene regions, SNPs were mapped to genes within 2 KB using *Biofilter* (assembly CRCh37.p10, genome build 104.0; Bush et al., [@B2]). Pathway analysis used Ingenuity Pathway Analysis (IPA) (Ingenuity® Systems, [www.ingenuity.com](http://www.ingenuity.com)).

Results {#s3}
=======

We examined the relationships of *in vitro* phenotypes with time to recurrence of EOC (40 of 74 patients had recurred or died). Of the 74 patients with LCLs included in this study, 51 had available information on the first two treatments used: 43 patients were treated with paclitaxel / carboplatin, 2 treated with paclitaxel/cisplatin, 3 treated with carboplatin/topotecan, and 3 treated with carboplatin/other less common agent. Paclitaxel *in vitro* drug response phenotypes were moderately associated with time to EOC recurrence (HR = 1.90 per unit increase in MTT IC50, *p* = 0.008; HR = 1.84 per unit increase in caspase 3/7 EC50, *p* = 0.058; Figure [1](#F1){ref-type="fig"}; Supplemental Table [2](#SM1){ref-type="supplementary-material"}). This suggests that patients whose LCLs demonstrated greater sensitivity to the chemotherapeutics tested had improved outcome; as Figure [1](#F1){ref-type="fig"} illustrates, LCLs that were sensitive to paclitaxel (as reflected by having low IC50 and low EC50 values) were from patients with longer time to progression as compared to patients with LCLs with high values. Although based on a small sample size, this provides, for the first time, a link between *in vitro* chemo-sensitivity testing and clinical outcome in EOC.

![**Kaplan-Meier curves for time to progression and paclitaxel *in vitro* phenotypes**. The groupings were defined by 3 quartiles representing low, medium or high values for the phenotype based **(A)** MTT assay IC50 or **(B)** Caspase 3/7 EC50 assay. The *p*-value presented is from a Cox proportional hazards model with the *in vitro* phenotype modeled as a continuous measurement on the log-scale.](fgene-07-00037-g0001){#F1}

Results of genome-wide association analyses for each drug response phenotype are presented in Figure [2](#F2){ref-type="fig"}. Regions with *p* \< 10^−6^ are highlighted and are further displayed in Figure [3](#F3){ref-type="fig"}. Table [1](#T1){ref-type="table"} presents the SNPs associated with the drug response phenotype with *p* \< 10^−6^. Overall, we found a greater proportion of significant results (e.g., at *p* \< 10^−6^) for the combination therapy as compared to the single agent therapies. In particular, we found strong SNP associations with combination therapy in the following gene regions: *SLC9A9* (MAF = 0.41, *p* = 6 × 10^−7^), *TIAL1* (MAF = 0.23, *p* = 7.3 × 10^−7^), *ZNF731P* (MAF = 0.39, *p* = 6.6 × 10^−7^), and *PCDH20* (MAF = 0.42, *p* = 8.2 × 10^−7^). None of these regions were found to be moderately associated with single agent carboplatin or paclitaxel IC50 in other pharmacogenomic studies involving commercially available LCLs (Huang et al., [@B17]; Niu et al., [@B34]).

![**Manhattan plots of the single SNP meta-analysis genome-wide association results based the six *in vitro* drug response measures among ovarian cancer patient LCLs. (A)** Carboplatin MTT; **(B)** Paclitaxel MTT; **(C)** Combination of carboplatin and paclitaxel MTT; **(D)** Carboplatin Caspase3/7; **(E)** Paclitaxel Caspase3/7; and **(F)** Combination of carboplatin and paclitaxel Caspase3/7. Blue line indicates *p* = 0.00001; Red line indicates *p* = 5 × 10^−8^. Highlighted regions (circled) are displayed in Figure [3](#F3){ref-type="fig"}.](fgene-07-00037-g0002){#F2}

![**Locus Zoom plots for regions with *p* \< 10^−6^**. Note: BOD1L1 region not presented as only one SNP in region with *p* \< 0.001.](fgene-07-00037-g0003){#F3}

###### 

**SNPs with *p* \< 10^−6^ association with a drug response phenotype**.

  **Drug**      **Phenotype**      **Nearest gene**                                     **SNP**       **Chr**   **Position**   **MAF**   **Meta-Analysis P**   **Group 1 (*****N*** = **33)**   **Group 2 (*****N*** = **41)**            
  ------------- ------------------ ---------------------------------------------------- ------------- --------- -------------- --------- --------------------- -------------------------------- -------------------------------- -------- ---------
  Paclitaxel    MTT IC50           *BOD1L1*                                             rs185229225   4         13609129       0.02      2.2E-07               −2.53                            8.0E-03                          −11.64   4.7E-06
                Caspase 3/7 EC50   *MGC32805/SNCAIP[^\*^](#TN1){ref-type="table-fn"}*   rs3842595     5         121778606      0.14      2.6E-07               −1.37                            1.7E-03                          −1.34    4.1E-05
  Carboplatin   MTT IC50           *FRAS1*                                              rs150303591   4         79009309       0.29      5.9E-07               0.86                             2.5E-03                          1.02     6.3E-05
  Combination   MTT IC50           *SLC9A9[^\*^](#TN1){ref-type="table-fn"}*            rs201023017   3         143103669      0.41      6.0E-07               0.84                             5.2E-04                          0.70     3.3E-04
                                   *TIAL1*                                              rs66696671    10        121366953      0.23      7.3E-07               −0.89                            2.9E-04                          −0.76    6.6E-04
                Caspase 3/7 EC50   *ZNF731P*                                            rs12025262    1         247356732      0.39      6.6E-07               −0.84                            2.5E-04                          −0.71    6.9E-04
                                   *PCDH20*                                             rs10674174    13        61892075       0.42      8.2E-07               −0.73                            5.3E-03                          −0.86    3.7E-05

*Nearest gene within 2000 base pairs*.

*For regions with multiple SNPs with p \< 10^−6^, the most significant SNP is presented. A negative estimate indicates that carriers of the minor allele had, on average, lower IC50 or EC50 ("sensitive") while a positive estimate indicates that carriers of the minor allele had, on average, higher IC50 or EC50 ("resistant")*.

We evaluated potential overlap of loci associated with both phenotypes for a given drug. Only one SNP was found to be associated with a *p* \< 10^−4^ with same direction of the effect for MTT IC50 and caspase3/7 EC50 values for paclitaxel, carboplatin, or combination treatment. An intronic SNP rs35067965 in *COLEC12* (chromosome 18, bp 455396) was associated with response to paclitaxel (MTT IC50 *p* = 2.2 × 10^−5^, caspase 3/7 EC50 *p* = 3.8 × 10^−5^; Table [2](#T2){ref-type="table"}). We also examined overlap of associations at the level of genes, considering SNPs within 20 kb. This showed consistency of IC50 and EC50 results for paclitaxel response and *COLEC12* and revealed similar IC50 and EC50 associations for carboplatin response in the gene regions of *CTIF* and *CDH4*. As presented in Table [3](#T3){ref-type="table"}, additional regions showed joint associations with response to multiple drugs, including variants in protein coding regions of *BRE, EML6, CTNNA2, LRP1B, EYS, NKAIN2, ANTXRL, COL13A1*, and *MTCL1* (SNPs in gene regions with *p* \< 0.0001).

###### 

**Gene regions with SNPs associated with both phenotypes for a given drug**.

  **Drug**      **Gene**    **Phenotype**      **SNP[^\*^](#TN2){ref-type="table-fn"}**   **Chr**   **Position**   ***P***   **Direction[^†^](#TN3){ref-type="table-fn"}**
  ------------- ----------- ------------------ ------------------------------------------ --------- -------------- --------- -----------------------------------------------
  Paclitaxel    *COLEC12*   MTT IC50           rs35067965                                 18        455396         2.2E-05   −−
                            Caspase 3/7 EC50   rs35067965                                 18        455396         3.8E-05   −−
  Carboplatin   *CTIF*      MTT IC50           rs8091660                                  18        46087936       8.9E-06   −−
                            Caspase 3/7 EC50   rs113867814                                18        46259604       1.2E-05   −−
                *CDH4*      MTT IC50           rs2748151                                  20        60133486       4.7E-05   ++
                            Caspase 3/7 EC50   rs113594423                                20        60379048       2.4E-05   ++

*Presenting most significant SNP in the region for the giving drug/phenotype. SNP within ± 20 KB of the listed gene*.

*A negative estimate indicates that carriers of the minor/variant allele had, on average, lower IC50 or EC50 ("sensitive") while a positive estimate indicates that carriers of the minor/variant allele had, on average, higher IC50 or EC50 ("resistant")*.

###### 

**Gene regions with SNPs associated with multiple drugs for any phenotype (*p* \< 0.0001)**.

  **Gene**      **Drug**      **Phenotype**      **SNP[^\*^](#TN4){ref-type="table-fn"}**   **Chr**   **Position**   ***P***   **Direction[^†^](#TN5){ref-type="table-fn"}**
  ------------- ------------- ------------------ ------------------------------------------ --------- -------------- --------- -----------------------------------------------
  *BRE*         Carboplatin   Caspase 3/7 EC50   rs5830067                                  2         28537890       1.7E-05   ++
                Combination   Caspase 3/7 EC50   rs7572644                                  2         28320033       5.8E-06   −−
  *EML6*        Paclitaxel    Caspase 3/7 EC50   rs75314082                                 2         55087315       7.9E-05   −−
                Combination   MTT IC50           rs17046344                                 2         55023600       4.9E-05   ++
  *LINC01122*   Paclitaxel    Caspase 3/7 EC50   rs72817940                                 2         58998563       6.4E-05   ++
                Carboplatin   Caspase 3/7 EC50   rs4233974                                  2         59295043       2.6E-05   −−
  *CTNNA2*      Carboplatin   MTT IC50           rs17261321                                 2         80197843       3.6E-05   ++
                Combination   MTT IC50           rs6719499                                  2         80193386       6.0E-05   −−
  *LRP1B*       Paclitaxel    MTT IC50           rs1525599                                  2         141778702      8.6E-05   ++
                Combination   Caspase 3/7 EC50   rs13020675                                 2         142212928      6.2E-05   −−
  *EYS*         Paclitaxel    Caspase 3/7 EC50   rs201083182                                6         65736914       2.3E-06   −−
                Combination   Caspase 3/7 EC50   rs2064701                                  6         65676556       3.6E-05   ++
  *NKAIN2*      Paclitaxel    Caspase 3/7 EC50   rs550987                                   6         124905510      4.1E-05   −−
                Combination   Caspase 3/7 EC50   rs670616                                   6         124885773      7.8E-05   ++
  *C7orf65*     Carboplatin   Caspase 3/7 EC50   rs10230114                                 7         47705506       2.4E-05   ++
                Combination   Caspase 3/7 EC50   rs11771997                                 7         47712495       2.4E-05   ++
  *ANTXRL*      Paclitaxel    Caspase 3/7 EC50   rs12572446                                 10        47665906       4.3E-05   ++
                Combination   Caspase 3/7 EC50   rs10906942                                 10        47670851       4.9E-05   ++
  *COL13A1*     Carboplatin   Caspase 3/7 EC50   rs10999018                                 10        71654602       2.4E-05   ++
                Combination   Caspase 3/7 EC50   rs77535242                                 10        71652985       3.5E-05   ++
  *TMEM132D*    Paclitaxel    Caspase 3/7 EC50   rs77438645                                 12        130304313      −−        −−
                Carboplatin   Caspase 3/7 EC50   rs1451904                                  12        130166947      6.5E-05   ++
  *MTCL1*       Carboplatin   Caspase 3/7 EC50   rs690089                                   18        8845223        7.8E-05   −−
                Combination   Caspase 3/7 EC50   rs35765215                                 18        8839469        6.0E-05   −−

*Presenting most significant SNP in the region for the giving drug/phenotype. SNP within ± 20 KB of the listed gene*.

*A negative estimate indicates that carriers of the minor/variant allele had, on average, lower IC50 or EC50 ("sensitive") while a positive estimate indicates that carriers of the minor/variant allele had, on average, higher IC50 or EC50 ("resistant")*.

Because of the suggested association between *in vitro* paclitaxel MTT IC50 response and time to EOC recurrence (Supplemental Table [2](#SM1){ref-type="supplementary-material"}), we also examined recurrence association with SNPs rs185229225 (intronic *BOD1L1*) rs35067965 (intronic *COLEC12*) and rs1525599 (intronic *LRP1B*) which were associated with paclitaxel MTT IC50 (Tables [1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}, respectively). However, none of these SNPs were associated with time to recurrence with a nominal *p* \< 0.05 (data not shown).

Discussion {#s4}
==========

In this proof of concept study, we explored use of LCLs derived from EOC patients followed for clinical response as a model for discovery of pharmacogenomics markers. LCLs were treated with varying concentration of the chemotherapeutics agents (carboplatin and paclitaxel and, uniquely, their combination) that were used for the treatment and cellular chemo-sensitivity was determined by measuring cell viability and activation of caspase activity (as a marker of apoptosis) post drug treatment. Genome-wide association studies were performed to identify inherited markers associated with these measures of *in vitro* chemo-sensitivity (i.e., MTT IC50 and caspase 3/7 EC50 values) and the relationships between *in vitro* measures and clinical outcome was explored.

Although the sample size was small limiting the power of the study, some of the implicated biologically interesting genes are worthy of discussion. Pathway analysis of genes with SNPs showing association with one of the drug response phenotypes (at *p* \< 10^−6^), both phenotypes for a given drug (at *p* \< 10^−4^), or multiple drugs for any phenotype (at *p* \< 10^−4^) found enrichment in genes related to malignant solid tumor and epithelial cancers (Supplemental Figure [2A](#SM1){ref-type="supplementary-material"}). Among the top canonical pathways represented by these genes were "Epithelial Adherens Junction Signaling," "Sertoli Cell Junction Signaling," and "Endometrial Cancer Signaling" (Supplemental Figure [2B](#SM1){ref-type="supplementary-material"}).

In addition, genes such as *CTNNA2* and *CDH4*, both tumor suppressor genes with role in cell adhesion were found to be associated with chemo-sensitivity in carboplatin alone or combination treatments. SNPs in *CTNNA2*- catenin (cadherin-associated protein) alpha2, a structural constituent of cytoskeleton and cadherin binding was associated with *in vitro* cytotoxicity to carboplatin alone as well as in combination with paclitaxel. CTNNA2 has been shown to be frequently mutated in laryngeal carcinomas with mutations predictive of poor prognosis (Fanjul-Fernandez et al., [@B8]). Additionally, SNPs within *CTNNA2* have recently been implicated in breast cancer (Haryono et al., [@B13]) and its role in tumor progression and metastasis has been suggested for multiple cancers (Mcgranahan et al., [@B29]). Variants in *CTNNA2* have also been implicated in schizophrenia (Mexal et al., [@B30]) and alcohol addiction (Song and Zhang, [@B43]). CTNNA2 SNPs associated with carboplatin and paclitaxel MTT IC50 were both intronic and present functional relevance of these is not known. *CDH4*, codes for cadherin, and has been implicated in nasopharyngeal carcinoma (Du et al., [@B6]) and aberrant methylation of CDH4 promoter has been colorectal and gastric cancer (Miotto et al., [@B31]). Our results identified two intronic SNPs (rs2748151 and rs113594423) that were associated with carboplatin resistant as measured by cell death (IC50) and apoptosis (caspase 3/7 EC50). Variants in *PCDH20*, another member of cadherin family, were also found to be associated *in vitro* drug response. *PCHD20* codes for protocadherin20 and functions as a tumor suppressor by interacting with Wnt/b-catenin signaling (Chen et al., [@B3]; Lv et al., [@B26]).

Another gene with role in cell adhesion identified in our study was *FRAS1*, which encodes for an extracellular matrix protein and is involved in the regulation of epidermal-basement membrane adhesion and organogenesis during development. Inherited mutations in *FRAS1*, and *FREM2*, have been associated with development of Fraser syndrome. *FRAS1* has also been implicated in ERK signaling and influence migration and invasion of lung cancer cell line by influencing FAK signaling (Zhan et al., [@B48]), suggesting its role in tumorigenesis and metastasis of lung cancer. Although the genes described above are involved cell adhesion/cell migration, the functional significance of the intronic SNPs identified in this study is not known and would require further investigation.

Two intronic variants within *BRE* were found to be associated with caspase 3/7 levels for carboplatin and combination therapy (indel rs5830067 and rs7572664). *BRE* encodes for Brain and reproductive Organ-Expressed (TNFRSF1A modulator) and is a component of BRCA1-A DNA damage repair complex that recognizes Lys 62linked ubiquitinated H2A and H2Ax at DNA lesions, resulting in recruitment of BRCA1-BARD1 to double strand DNA breaks (Li et al., [@B24]). *BRE* expression has been shown to be predictive of disease free survival in non-familial breast cancer patients (Noordermeer et al., [@B35]) and recent studies show its involvement in both intrinsic and extrinsic apoptotic pathways by influencing *XIAP* (Chui et al., [@B4]). Variation within *EML6*, which is involved assembly dynamics of microtubules, was found to be associated with platinum-sensitivity which was of interest since paclitaxel\'s mechanism of action involved disruption of microtubules; however no evidence exists in the literature on functional relevance of these particular SNPs within *EML6*. No other genes involved in microtubule protein were identified with respect to paclitaxel chemo-sensitivity.

Lastly, two intronic variants within *LRP1B* (low density lipoprotein related protein 1B) were associated with paclitaxel and combination therapy drug response phenotypes. *LRP1B* is a tumor suppressor with decreased expression in several primary cancers and is among 10 most significantly deleted genes across 3312 cancer samples (Langbein et al., [@B21]; Sonoda et al., [@B44]; Nakagawa et al., [@B32]; Prazeres et al., [@B39]). In renal cell cancer, down-regulation of *LRP1B* has been shown to regulate cell motility and actin cytoskeleton reorganization (Lu et al., [@B25]). Germline SNPs/ haplotype in *LRP1B* have been associated with aging without cognitive decline (Poduslo et al., [@B38]); however, associations of germline SNPs with incidence/progression of cancer and pharmacogenomics have yet to be reported.

In summary, using a patient-derived cell-based model system to generate several *in vitro* drug response phenotypes on a clinically followed set of EOC cases we have identified genetic loci associated with response to platinum-taxane therapies. Overall our results identified germ-line SNPs in multiple cell adhesion molecules and several tumor suppressor genes (*PCDH20, LRP1B, CDH4*, and *CTNNA2*). However, none of the most associated SNPs were reported by Huang et al. ([@B17]) or associated with mRNA gene expression in lymphoblastoid cell lines (<http://www.ncbi.nlm.nih.gov/projects/gap/eqtl/index.cgi>). Further studies are needed to determine if these SNPs are truly associated with drug response or if they represent false-positive findings. Similar to other studies comparing *in vitro* chemo-sensitivity with clinical outcomes (Huang et al., [@B17]; Gamazon et al., [@B11]), our findings suggest that *in vitro* response to paclitaxel correlates with time to disease recurrence indicating that this model may have utility in several types of future studies. On possible explanation for the observation that paclitaxel correlates with recurrence and not carboplatin may be the fact that the majority of EOC patients eventually develop platinum resistant tumors and the main factor related to future response maybe attributed to response to taxane therapy. Further research is needed to understand the mechanism by which genomic loci impact clinical response in ovarian cancer patients to the most common regimen used in the treatment of ovarian cancer following surgery.
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